Mirum Pharmaceuticals Inc
NASDAQ:MIRM

  • LAST PRICE
    26.6800
  • TODAY'S CHANGE (%)
    -0.3200 (-1.1852%)
  • Bid / Lots
    25.7900/ 1
  • Ask / Lots
    27.5300/ 1
  • Open / Previous Close
    27.1600 / 27.0000
  • Day Range
    26.2800
    27.7000
  • 52 Week Range
    23.1400
    35.5600
  • Volume
    405,237

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
MIRM
Mirum Pharmaceuticals Inc
1.2B
-7.0x
---
MNKD
MannKind Corp
1.3B
215.1x
---
XNCR
Xencor Inc
1.4B
-9.7x
---
ARCT
Arcturus Therapeutics Holdings Inc
871.5M
-7.9x
---
AUPH
Aurinia Pharmaceuticals Inc
793.8M
-12.3x
---
DNA
Ginkgo Bioworks Holdings Inc
1.1B
-1.1x
---
As of 2024-06-13

Company Information

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Contact Information

Headquarters
989 EAST HILLSDALE BOULEVARD, SUITE 300FOSTER CITY, CA, United States 94404
Phone
650-667-4085
Fax
302-269-3855

Executives

Independent Non-Executive Chairman of the Board
Michael Grey
President, Chief Operating Officer
Peter Radovich
Chief Executive Officer, Co-Founder, Director
Christopher Peetz
Chief Financial Officer
Eric Bjerkholt
Chief Scientific Officer
Pamela Vig

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.2B
Revenue (TTM)
$224.0M
Shares Outstanding
47.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.10
EPS
$-3.82
Book Value
$5.32
P/E Ratio
-7.0x
Price/Sales (TTM)
5.5
Price/Cash Flow (TTM)
---
Operating Margin
-70.34%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.